$LNTH
Lantheus Holdings, Inc. Stock $lnth

$lnth Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000162828020002197 Filed on February 25, 2020

Income Statement

Concept	2019 Q4	2018 Q4	2018 Q3
Revenue	$89.35M	$86.27M	$88.90M
YoY Change	3.56%	6.19%	11.21%
Cost Of Revenue	$44.78M	$42.43M	$44.02M
YoY Change	5.54%	-2.1%	6.28%
Gross Profit	$44.57M	$43.85M	$44.89M
YoY Change	1.64%	15.69%	16.5%
Gross Profit Margin	49.88%	50.82%	50.49%
Selling, General & Admin	$27.69M	$22.35M	$24.09M
YoY Change	23.89%	-9.59%	8.74%
% of Gross Profit	62.13%	50.98%	53.66%
Research & Development	$4.430M	$4.550M	$4.316M
YoY Change	-2.64%	14.32%	21.44%
% of Gross Profit	9.94%	10.38%	9.62%
Depreciation & Amortization	$3.540M	$3.390M	$3.450M
YoY Change	4.42%	-19.48%	-8.0%
% of Gross Profit	7.94%	7.73%	7.69%
Operating Expenses	$32.13M	$26.90M	$28.40M
YoY Change	19.44%	-6.27%	10.5%
Operating Profit	$12.44M	$16.95M	$16.48M
YoY Change	-26.62%	84.2%	28.54%
Interest Expense	-$2.080M	-$4.970M	$4.446M
YoY Change	-58.15%	8.99%	0.09%
% of Operating Profit	-16.73%	-29.33%	26.97%
Other Income/Expense, Net	-$7.960M	$770.0K	$799.0K
YoY Change	-1133.77%	-88.84%	-12.0%
Pretax Income	$2.400M	$12.74M	$12.84M
YoY Change	-81.16%	13.14%	38.19%
Income Tax	-$8.050M	$4.000M	$3.566M
% Of Pretax Income	-335.42%	31.4%	27.78%
Net Earnings	$10.45M	$13.29M	$9.269M
YoY Change	-21.39%	-86.31%	8.71%
Net Earnings / Revenue	11.7%	15.41%	10.43%
Basic Earnings Per Share	$0.27	$0.35	$0.24
Diluted Earnings Per Share	$0.26	$0.34	$0.24
COMMON SHARES
Basic Shares Outstanding	39.25M shares	38.46M shares	38.34M shares
Diluted Shares Outstanding			39.40M shares

Balance Sheet

Concept	2019 Q4	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$92.90M	$113.4M	$104.6M
YoY Change	-18.08%	48.62%	53.6%
Cash & Equivalents	$92.92M	$113.4M	$104.6M
Short-Term Investments
Other Short-Term Assets	$7.283M	$5.242M	$4.669M
YoY Change	38.94%	0.4%	23.23%
Inventory	$29.18M	$33.02M	$34.57M
Prepaid Expenses
Receivables	$43.53M	$43.75M	$47.14M
Other Receivables	$0.00	$300.0K	$0.00
Total Short-Term Assets	$172.9M	$195.4M	$191.0M
YoY Change	-11.52%	32.17%	39.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$116.5M	$107.9M	$99.41M
YoY Change	7.98%	16.01%	5.17%
Goodwill	$15.71M	$15.71M	$15.71M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$7.336M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$21.63M	$30.23M	$29.65M
YoY Change	-28.46%	6.13%	37.69%
Total Long-Term Assets	$233.0M	$244.4M	$233.9M
YoY Change	-4.67%	3.56%	61.94%
TOTAL ASSETS
Total Short-Term Assets	$172.9M	$195.4M	$191.0M
Total Long-Term Assets	$233.0M	$244.4M	$233.9M
Total Assets	$405.9M	$439.8M	$424.8M
YoY Change	-7.71%	14.58%	51.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.61M	$17.96M	$20.36M
YoY Change	3.64%	2.81%	8.57%
Accrued Expenses	$37.40M	$32.10M	$31.50M
YoY Change	16.51%	21.13%	28.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.14M	$2.750M	$2.750M
YoY Change	268.84%	0.0%	0.0%
Total Short-Term Liabilities	$66.11M	$52.76M	$54.58M
YoY Change	25.32%	12.84%	18.42%
LONG-TERM LIABILITIES
Long-Term Debt	$183.9M	$263.7M	$264.1M
YoY Change	-30.25%	-0.63%	-0.52%
Other Long-Term Liabilities	$28.40M	$40.79M	$39.32M
YoY Change	-30.39%	7.32%	5.77%
Total Long-Term Liabilities	$212.3M	$304.5M	$303.5M
YoY Change	-30.27%	0.36%	0.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$66.11M	$52.76M	$54.58M
Total Long-Term Liabilities	$212.3M	$304.5M	$303.5M
Total Liabilities	$291.3M	$368.8M	$369.3M
YoY Change	-21.02%	2.29%	2.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$136.5M	-$168.1M	-$181.4M
YoY Change	-18.83%	-19.56%	-40.74%
Common Stock	$252.0M	$240.3M	$238.0M
YoY Change	4.9%	2.96%	3.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$114.6M	$71.00M	$55.51M
YoY Change
Total Liabilities & Shareholders Equity	$405.9M	$439.8M	$424.8M
YoY Change	-7.71%	14.58%	51.17%

Cashflow Statement

Concept	2019 Q4	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	$10.45M	$13.29M	$9.269M
YoY Change	-21.39%	-86.31%	8.71%
Depreciation, Depletion And Amortization	$3.540M	$3.390M	$3.450M
YoY Change	4.42%	-19.48%	-8.0%
Cash From Operating Activities	$22.42M	$17.30M	$24.28M
YoY Change	29.6%	32.16%	55.64%
INVESTING ACTIVITIES
Capital Expenditures	-$4.740M	-$7.360M	-$5.010M
YoY Change	-35.6%	23.7%	52.28%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$4.740M	-$7.360M	-$5.010M
YoY Change	-35.6%	23.7%	52.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.820M	-940.0K	-1.210M
YoY Change	200.0%	-181.74%	-20.39%
NET CHANGE
Cash From Operating Activities	22.42M	17.30M	24.28M
Cash From Investing Activities	-4.740M	-7.360M	-5.010M
Cash From Financing Activities	-2.820M	-940.0K	-1.210M
Net Change In Cash	14.86M	9.000M	18.06M
YoY Change	65.11%	8.56%	67.38%
FREE CASH FLOW
Cash From Operating Activities	$22.42M	$17.30M	$24.28M
Capital Expenditures	-$4.740M	-$7.360M	-$5.010M
Free Cash Flow	$27.16M	$24.66M	$29.29M
YoY Change	10.14%	29.52%	55.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001521036
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39252651	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q2	dei	Entity Public Float EntityPublicFloat	1090900000	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	LANTHEUS HOLDINGS, INC.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Trading Symbol TradingSymbol	LNTH
CY2018Q4	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	7721000	USD
CY2019Q4	lnth	Accrued Freight Costs Current AccruedFreightCostsCurrent	6260000	USD
CY2018Q4	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	4654000	USD
CY2019Q4	lnth	Accrued Rebates Discounts And Chargebacks Current AccruedRebatesDiscountsAndChargebacksCurrent	6985000	USD
CY2019Q4	lnth	Asset Retirement Obligation Liabilities Expected Present Value AssetRetirementObligationLiabilitiesExpectedPresentValue	26900000	USD
CY2019Q2	lnth	Capitalized Debt Issuance Cost CapitalizedDebtIssuanceCost	2800000	USD
CY2018Q4	lnth	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	2809000	USD
CY2019Q4	lnth	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	1569000	USD
CY2017	lnth	Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset	1055000	USD
CY2018	lnth	Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset	731000	USD
CY2019	lnth	Effective Income Tax Rate Reconciliation Increase In Indemnification Deferred Tax Asset EffectiveIncomeTaxRateReconciliationIncreaseInIndemnificationDeferredTaxAsset	-2531000	USD
CY2019	lnth	Expense From Reversal Of Indemnification Receivable ExpenseFromReversalOfIndemnificationReceivable	13800000	USD
CY2019	lnth	Financial Assurance In Form Of Surety Bond FinancialAssuranceInFormOfSuretyBond	28200000	USD
CY2018	lnth	Forfeiture Of Dividend Equivalent Rights ForfeitureOfDividendEquivalentRights	355000	USD
CY2019Q4	lnth	Lease Liability LeaseLiability	1334000	USD
CY2019Q4	lnth	Lease Right Of Use Asset LeaseRightOfUseAsset	1283000	USD
CY2017	lnth	Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit	-86946000	USD
CY2018	lnth	Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit	5762000	USD
CY2019	lnth	Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Deferred Income Tax Expense Benefit NoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesDeferredIncomeTaxExpenseBenefit	9725000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18608000	USD
CY2017	lnth	Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan	3434000	USD
CY2018	lnth	Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan	1580000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43753000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43529000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1673000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6917000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	82739000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1108000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-960000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	239865000	USD
CY2019Q4	lnth	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	91655000	USD
CY2019Q4	lnth	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	116497000	USD
CY2019Q4	lnth	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	208152000	USD
CY2019	lnth	Stock Issued During Period Value Stock Options Exercisedand Employee Stock Ownership Plan StockIssuedDuringPeriodValueStockOptionsExercisedandEmployeeStockOwnershipPlan	1746000	USD
CY2017	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	8367000	USD
CY2017	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	8400000	USD
CY2018	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	2855000	USD
CY2018	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	2900000	USD
CY2019	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	-10635000	USD
CY2019	lnth	Tax Indemnification Agreement Income Expense TaxIndemnificationAgreementIncomeExpense	-10600000	USD
CY2018Q4	lnth	Tax Indemnification Agreement Receivable TaxIndemnificationAgreementReceivable	29500000	USD
CY2019Q4	lnth	Tax Indemnification Agreement Receivable TaxIndemnificationAgreementReceivable	18900000	USD
CY2018Q4	lnth	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	40200000	USD
CY2019Q4	lnth	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	27000000	USD
CY2017	lnth	Valuation Allowancesand Reserves Releaseof Valuation Allowance ValuationAllowancesandReservesReleaseofValuationAllowance	141100000	USD
CY2017	lnth	Vesting Of Restricted Stock Awards Value VestingOfRestrictedStockAwardsValue	0	USD
CY2018	lnth	Vesting Of Restricted Stock Awards Value VestingOfRestrictedStockAwardsValue	0	USD
CY2019	lnth	Vesting Of Restricted Stock Awards Value VestingOfRestrictedStockAwardsValue	0	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	32050000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	37360000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17955000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	251641000	USD
CY2017	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2853000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3386000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2454000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5928000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8718000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12492000	USD
CY2017	us-gaap	Advertising Expense AdvertisingExpense	4400000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	4000000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	3800000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5928000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8718000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12492000	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1361000	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1279000	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	978000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3300000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	604000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	424000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50000	shares
CY2019	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1291000	USD
CY2019	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	20000	USD
CY2018Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	11572000	USD
CY2019Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	12883000	USD
CY2018Q4	us-gaap	Assets Assets	439831000	USD
CY2019Q4	us-gaap	Assets Assets	405919000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	195415000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	172911000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	61391000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	39530000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2738000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7395000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4175000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113401000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92919000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51178000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76290000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113401000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92919000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25112000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37111000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20482000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	250000	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38466000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39251000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38466000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39251000	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	385000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	393000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	123298000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	40444000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	31815000	USD
CY2018	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	33000	USD
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	33000	USD
CY2018	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2019	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2017	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	14800000	USD
CY2018	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	10100000	USD
CY2019	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	10300000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	169243000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	168489000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	172526000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-58000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-21000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	287000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	16000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-135000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	114000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3268000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12765000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3200000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3242000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3424000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-13166000	USD
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	195000000	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	485000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-71742000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	7821000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	8712000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	16000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3470000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	223000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	81449000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	71834000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-86946000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5762000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	9725000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2791000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1588000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-15220000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1411000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	790000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	85480000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	74660000	USD
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7491000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5086000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	428000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	550000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	81449000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	71834000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	55938000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47095000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	56000	USD
CY2018Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	7809000	USD
CY2019Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	5278000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	11005000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	15026000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1240000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1238000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1200000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	1078000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	881000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	986000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	707000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	727000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1800000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1800000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2017	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	19231000	USD
CY2018	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	13929000	USD
CY2019	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	13379000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18189000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12769000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12087000	USD
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.31
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.35
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.06
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.81
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.17
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.16
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-282000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15962000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15100000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	11000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	11000	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	329000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	143000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	186000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	354000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	135000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	83000	USD
CY2019Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	136000	USD
CY2019Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	25000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	190000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	348000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	167000	USD
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.054
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	109889000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	105223000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2208000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1568000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	496000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	579000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1174000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1311000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	119022000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	112559000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9133000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7336000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	253000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-557000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	33000	USD
CY2017	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2018	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2019	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	3453000	USD
CY2019Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3200000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2442000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3196000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-2442000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3196000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	49842000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50167000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	61244000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	15714000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	15714000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Gross Profit GrossProfit	162135000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	42309000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	43846000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	44885000	USD
CY2018Q4	us-gaap	Gross Profit GrossProfit	43845000	USD
CY2018	us-gaap	Gross Profit GrossProfit	174885000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	44084000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	44573000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	41589000	USD
CY2019Q4	us-gaap	Gross Profit GrossProfit	44565000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	635000	USD
CY2017	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	7000	USD
CY2018	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	0	USD
CY2019	us-gaap	Gross Profit GrossProfit	174811000	USD
CY2017	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	912000	USD
CY2018	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
CY2019	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	39559000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	46945000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	25432000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	39639000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	49548000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	28627000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	80000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2603000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3195000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	39639000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	49548000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	28627000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-83746000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9030000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3040000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-141094000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-4073000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-22000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	45129000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	97000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	30000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-238000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	13873000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	10405000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	6012000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1916000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	505000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3737000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2723000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1760000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2768000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-269000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	44000	USD
CY2019	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	0	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1252000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2125000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1914000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	3128000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	3227000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-13156000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	175000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	742000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	1685000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	106000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	90000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	274000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	604000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2886000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3233000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3407000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3985000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-156000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4495000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2250000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6077000	USD
CY2017	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	8413000	USD
CY2018	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2855000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-10635000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9620000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8690000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1994000	USD
CY2017	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	388000	USD
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	661000	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2411000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2793000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3219000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-13156000	USD
CY2017	us-gaap	Interest Expense InterestExpense	18410000	USD
CY2018	us-gaap	Interest Expense InterestExpense	17405000	USD
CY2019	us-gaap	Interest Expense InterestExpense	13617000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	16653000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	15869000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	12253000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17658000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8313000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	33019000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	29180000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	11100000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	11417000	USD
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4261000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9450000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	1851000	USD
CY2019Q4	us-gaap	Number Of Stores NumberOfStores	1	pharmacy
CY2017	us-gaap	Operating Expenses OperatingExpenses	110282000	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	1215000	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	2875000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	167000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	686000	USD
CY2019	us-gaap	Lease Cost LeaseCost	492000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1130000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	238000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	178000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	238000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	238000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	238000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	125000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	368829000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	291318000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	439831000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	405919000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	52755000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66111000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	194070000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2750000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10143000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	10000000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	148750000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	15000000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	11250000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10000000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	263709000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	183927000	USD
CY2019Q4	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0355
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13450000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4668000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-78881000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16309000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19132000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22061000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	54777000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	61193000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	80384000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	123385000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	8211000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	9745000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	9269000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	13293000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	40518000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	9949000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	6412000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	4856000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	10450000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	193000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	110397000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	123150000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	51853000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	64488000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	812000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	230000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	31667000	USD
CY2018Q4	us-gaap	Noncurrent Assets NoncurrentAssets	107888000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	116497000	USD
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	51661000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	223000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1005000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2465000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6221000	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1576000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2258000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	74000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2853000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8638000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	935000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.051
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10330000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4132000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2066000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4132000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2040000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2098000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5242000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7283000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30232000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21627000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-87000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-74000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	148000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-87000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-74000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	148000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40793000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28397000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1049000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1399000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-422000	USD
CY2017	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2018	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2019	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	242000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3386000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2454000	USD
CY2017	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	17543000	USD
CY2018	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	20132000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	343374000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86510000	USD
CY2019	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	22061000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	82630000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85573000	USD
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	17000	USD
CY2018	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	35000	USD
CY2019	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	2000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	187000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	428000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	573000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	274313000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	199461000	USD
CY2017	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1234000	USD
CY2018	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1000000	USD
CY2019	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3247000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1152000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1173000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	190627000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107888000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	136000	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	321000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	146000	USD
CY2019Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	0	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	286694000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2862000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	275376000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18125000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17071000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20018000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	200000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168140000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136473000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	331378000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	88900000	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86271000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85705000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85776000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	89346000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	347337000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	379000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2018Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	600000	USD
CY2019Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	600000	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	42315000	USD
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	43159000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	41888000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	5928000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	8718000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	12492000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	6580277	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	272224	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.44
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5100000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2400000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	600000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	17293	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	18.66
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1096000000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	357075	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	272224	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.50
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.44
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	17.37
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.00
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1096000000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y8M9D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M9D
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	91000	USD
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	465232	shares
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	192550	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	67558	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-106516000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	23291000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	71002000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	114601000	USD
CY2019Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	774000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9866000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9800000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9788000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5300000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5292000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	4000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	4496000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	28200000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	20700000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	2200000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	1000000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	12700000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-17100000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	74000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3300000	USD
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38892000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39501000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40113000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37276000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38233000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38988000	shares
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of Risks and Limited Suppliers</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of trade accounts receivable. The Company periodically reviews its accounts receivable for collectability and provides for an allowance for doubtful accounts to the extent that amounts are not expected to be collected. The Company sells primarily to large national distributors, which in turn, resell the Company’s products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">As of December 31, 2019, </font><font style="font-family:Times New Roman;font-size:10pt;">no</font><font style="font-family:Times New Roman;font-size:10pt;"> customer accounted for greater than 10% of accounts receivable, net. </font><font style="font-family:Times New Roman;font-size:10pt;">One</font><font style="font-family:Times New Roman;font-size:10pt;"> customer accounted for approximately </font><font style="font-family:Times New Roman;font-size:10pt;">11%</font><font style="font-family:Times New Roman;font-size:10pt;"> of accounts receivable, net for the year ended December 31, 2018. No customer accounted for greater than 10% of revenues for the years ended December 31, 2019 and December 31, 2018. </font><font style="font-family:Times New Roman;font-size:10pt;">Three</font><font style="font-family:Times New Roman;font-size:10pt;"> customers accounted for approximately </font><font style="font-family:Times New Roman;font-size:10pt;">12%</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">10%</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">10%</font><font style="font-family:Times New Roman;font-size:10pt;"> of revenues for the year ended December 31, 2017.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Company relies on certain materials used in its development and manufacturing processes, some of which are procured from only one or a few sources. The failure of one of these suppliers to deliver on schedule could delay or interrupt the manufacturing or commercialization process and would adversely affect the Company’s operating results. In addition, a disruption in the commercial supply of, or a significant increase in the cost of one of the Company’s materials from these sources could have a material adverse effect on the Company’s business, financial position and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Company has Mo-99 supply agreements with IRE of Belgium, running through December 31, 2022, and renewable by the Company on a year-to-year basis thereafter, and with ANSTO and NTP, running through December 31, 2021. The Company also has a Xenon supply agreement with IRE which runs through June 30, 2022, and which is subject to further extension. The Company currently relies on IRE as the sole supplier of bulk-unprocessed Xenon which the Company processes and finishes for its customers. The Company currently relies on JHS as its sole source manufacturer of DEFINITY, Neurolite, Cardiolite and evacuation vials for TechneLite.</font></div></div>
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Description of Business</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Lantheus Holdings, Inc., a Delaware corporation, is the parent company of Lantheus Medical Imaging, Inc. (“LMI”), also a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Company develops, manufactures and commercializes innovative diagnostic medical imaging agents and other products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. The Company sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Company sells its products globally and has operations in the U.S., Puerto Rico and Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific and Latin America.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Company’s product portfolio includes an ultrasound contrast agent, nuclear imaging products and a radiotherapeutic product. The Company’s principal products include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">DEFINITY</font><font style="font-family:inherit;font-size:10pt;"> is a microbubble contrast agent used in ultrasound exams of the heart, also known as echocardiography exams. DEFINITY contains perflutren-containing lipid microspheres and is indicated in the U.S. for use in patients with suboptimal echocardiograms to assist in imaging the left ventricular chamber and left endocardial border of the heart in ultrasound procedures.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">TechneLite</font><font style="font-family:inherit;font-size:10pt;"> is a Tc-99m generator that provides the essential nuclear material used by radiopharmacies to radiolabel Cardiolite, Neurolite and other Tc-99m-based radiopharmaceuticals used in nuclear medicine procedures. TechneLite uses Mo-99 as its active ingredient.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Sales of the Company’s microbubble contrast agent, DEFINITY, are made in the U.S. and Canada through a DEFINITY direct sales team. In the U.S., the Company’s nuclear imaging products, including TechneLite, Xenon, Neurolite and Cardiolite, are primarily distributed through commercial radiopharmacies, the majority of which are controlled by or associated with GE Healthcare, Cardinal, UPPI, Jubilant Radiopharma and PharmaLogic. A small portion of the Company’s nuclear imaging product sales in the U.S. are made through the Company’s direct sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical preparation capabilities. The Company owns </font><font style="font-family:Times New Roman;font-size:10pt;">one</font><font style="font-family:Times New Roman;font-size:10pt;"> radiopharmacy in Puerto Rico where they sell their own products as well as products of third parties to end-users.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Company also maintains its own direct sales force in Canada for certain of its products. In Europe, Australia, Asia-Pacific and Latin America, the Company generally relies on third-party distributors to market, sell and distribute its nuclear imaging and contrast agent products, either on a country-by-country basis or on a multi-country regional basis.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Progenics Transaction</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">On October 1, 2019, the Company entered into an Agreement and Plan of Merger (the “Initial Merger Agreement”) to acquire Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”) in an all-stock transaction. Progenics is an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. Under the terms of the Initial Merger Agreement, the Company agreed to acquire all of the issued and outstanding shares of Progenics common stock at a fixed exchange ratio. Progenics stockholders would have received </font><font style="font-family:Times New Roman;font-size:10pt;">0.2502</font><font style="font-family:Times New Roman;font-size:10pt;"> shares of the Company’s common stock for each share of Progenics common stock, representing an approximately </font><font style="font-family:Times New Roman;font-size:10pt;">35%</font><font style="font-family:Times New Roman;font-size:10pt;"> aggregate ownership stake in the combined company. The transaction contemplated by the Initial Merger Agreement was unanimously approved by the Boards of Directors of both companies and was subject to the terms and conditions set forth in the Initial Merger Agreement, including, among other things, the affirmative vote of a majority of the outstanding shares of common stock of Progenics and a majority of votes cast by the holders of the common stock of the Company.  The Initial Merger Agreement further provides that in the event of a termination of the Initial Merger Agreement under certain circumstances, one party may be required to pay the other party a termination fee equal to </font><font style="font-family:Times New Roman;font-size:10pt;">$18.3 million</font><font style="font-family:Times New Roman;font-size:10pt;">. In the event of a termination of the Merger Agreement as a result of Progenics stockholders failing to adopt the Initial Merger Agreement, Progenics may be required to reimburse reasonable and documented out-of-pocket expenses incurred by the Company in connection with the Merger Agreement not to exceed </font><font style="font-family:Times New Roman;font-size:10pt;">$5.3 million</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">On February 20, 2020, the Company entered into an Amended and Restated Agreement and Plan of Merger (the “Amended Merger Agreement”) with Progenics that, among other things, increases the exchange ratio and provides for the issuance of CVRs in connection with the transaction. See Note 20, “Subsequent Events” for further details on the Amended Merger Agreement.</font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities and accrued expenses. Actual results could materially differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-20-002197-index-headers.html	Edgar Link	pending
0001628280-20-002197-index.html	Edgar Link	pending
0001628280-20-002197.txt	Edgar Link	pending
0001628280-20-002197-xbrl.zip	Edgar Link	pending
chart-c697fe58cd29546f828.jpg	Edgar Link	pending
ex1034priceandvolumeagreem.htm	Edgar Link	pending
ex211subsidiaries.htm	Edgar Link	pending
ex231consent.htm	Edgar Link	pending
ex311ceocertification.htm	Edgar Link	pending
ex312cfocertification.htm	Edgar Link	pending
ex321ceocfocertification.htm	Edgar Link	pending
ex42descriptionofregistran.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lnth-20191231.xml	Edgar Link	completed
lnth-20191231.xsd	Edgar Link	pending
lnth-20191231_cal.xml	Edgar Link	unprocessable
lnth-20191231_def.xml	Edgar Link	unprocessable
lnth-20191231_lab.xml	Edgar Link	unprocessable
lnth-20191231_pre.xml	Edgar Link	unprocessable
lnth_12312019x10k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LNTH
Lantheus Holdings, Inc. Stock $lnth

2019 Q4 Form 10-K Financial Statement

#000162828020002197 Filed on February 25, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH Lantheus Holdings, Inc. Stock $lnth

2019 Q4 Form 10-K Financial Statement

#000162828020002197 Filed on February 25, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNTH
Lantheus Holdings, Inc. Stock $lnth